Abstract Each year, the American Cancer Society estimates the numbers of new cancer
cases and deaths in the United States and compiles the most recent data on population …

Endometrial cancer (EC) is the most common gynaecological cancer among women in high-
income countries, with both incidence and mortality continuing to increase. The complexity …

Background Paclitaxel and carboplatin is the standard chemotherapy for the treatment of
advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell …

Background At the time of AtTEnd trial design, standard treatment for advanced or recurrent
endometrial cancer included carboplatin and paclitaxel chemotherapy. This trial assessed …

Background Numerous studies have shown that older women with endometrial cancer have
a higher risk of recurrence and cancer-related death. However, it remains unclear whether …

Background Immunotherapy combined with chemotherapy significantly improves
progression-free survival (PFS) compared to first-line chemotherapy alone in advanced …

Background Immune checkpoint inhibitors (ICIs) have uncommon associations with
cardiotoxicity, yet these cardiotoxic effects are associated with high mortality. An accurate …

Importance Various randomized trials have explored the efficacy of combining immune
checkpoint inhibitors (ICIs) with first-line chemotherapy in advanced endometrial cancer. We …

Background Currently, several randomized controlled trials (RCTs) have been conducted to
investigate the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy …

In the 2023 series, we summarized the major clinical research advances in gynecologic
oncology based on communications at the conference of Asian Society of Gynecologic …